Trends in Venous Thromboembolism Readmission Rates after Ischemic Stroke and Intracerebral Hemorrhage

Article information

J Stroke. 2023;25(1):151-159

Publication date (electronic) : 2023 January 3

doi : https://doi.org/10.5853/jos.2022.02215

Liqi Shu^a, Adam de Havenon^b, Ava L. Liberman^c, Nils Henninger^d,e, Eric Goldstein^a, Michael E. Reznik^a, Ali Mahta^a, Fawaz Al-Mufti^f,g, Jennifer Frontera^h, Karen Furie^a, Shadi Yaghi^,a

^aDepartment of Neurology, Brown University, Providence, RI, USA

^bDepartment of Neurology, Yale University, New Haven, CT, USA

^cDepartment of Neurology, Weill Cornell Medical Center, New York, NY, USA

^dDepartment of Neurology, University of Massachusetts, Worcester, MA, USA

^eDepartment of Psychiatry, University of Massachusetts, Worcester, MA, USA

^fDepartment of Neurology, Westchester Medical Center, Valhalla, NY, USA

^gDepartment of Neurosurgery, Westchester Medical Center, Valhalla, NY, USA

^hDepartment of Neurology, New York University, New York, NY, USA

Correspondence: Shadi Yaghi Department of Neurology, Brown Medical School, 593 Eddy Street APC 5, Providence, RI, 02903, USA Tel: +1-401-444-8806 Fax: +1-401-444-8781 E-mail: shadiyaghi@yahoo.com

Received 2022 July 8; Revised 2022 September 3; Accepted 2022 September 8.

Abstract

Introduction

Stroke is a leading cause of mortality and morbidity [1]. Advancements in acute stroke treatments and improved inpatient stroke care have led to decreased stroke-related mortality, but patients remain at risk for secondary complications [2].

Despite current preventative strategies, clinically evident venous thromboembolism (VTE) is an important post-stroke complication that occurs in up to 5% of immobile stroke patients within the first 30-days [3] and contributes to post-stroke mortality [4]. Therefore, understanding factors associated with such complications is of paramount importance to identify patients at risk and ultimately improve therapeutic measures to reduce VTE-associated morbidity and mortality after stroke.

While current treatments such as mechanical or chemical VTE prophylaxis, are generally utilized in hospitalized stroke patients [5], quality efforts do not generally oversee the use of such measures in the post-hospitalization phase, i.e., acute rehabilitation units and skilled nursing facilities. Furthermore, in patients with high risk of major bleeding such as patients with intracerebral hemorrhage (ICH), chemical prophylaxis is considered based on risk of VTE [6], and may be avoided or delayed [7]. Therefore, it is crucial to identify patients at high-risk for VTE after their initial stroke hospitalization who may benefit from continued VTE prophylactic measures beyond their initial inpatient hospital stay. In this study, we aim to determine predictors of VTE readmissions in both hemorrhagic and ischemic stroke patients and compare VTE risk in patients with ICH to those with acute ischemic stroke (AIS).

Methods

IRB approval was waived by Lifespan Institutional Review Board since our analysis used de-identified publicly available data. Informed consent was waived by the IRB as the dataset used is a publicly available de-identified. The Nationwide Readmissions Database (NRD) used for this analysis is publicly available through the Healthcare Cost and Utilization Project (HCUP) at https://www.hcup-us.ahrq.gov/.

Patient population

We included adult patients 18 years or older hospitalized with a principal diagnosis of AIS or non-traumatic ICH using the HCUP Nationwide Database between January 1st, 2016 and December 31st, 2019. Diagnoses were identified based on ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) codes (Supplementary Table 1). For stroke, when used as a primary diagnosis, ICD-10 code has a positive predictive value of 99.8% and a sensitivity of 87.2% [8]. We excluded patients with a new VTE diagnosis at the time of index stroke admission, a prior history of VTE, and patients who died during the index admission. Due to the inability of following patients across different years, patients who were discharged from October to December were excluded each year to allow a follow-up duration of 90 days. Since we are interested in the short-term risk of a VTE readmission in stroke patients, we also excluded patients whose index admission exceeded 30 days in duration (Figure 1).

Figure 1.

Flow chart of the study. AIS, acute ischemic stroke; ICH, intracerebral hemorrhage; VTE, venous thromboembolism. *Patients may have more than one exclusion reason.

Results

Study cohort and overall VTE rates

Of the 2,288,058 patients with AIS or ICH as their principal diagnosis in their index admission, 1,459,865 met the inclusion criteria (Figure 1 depicts the study flow chart). Among the 1,330,584 included AIS patients, the mean age was 70.0±0.1 years, 49.6% (660,175/1,330,584) were women, and 3,407 (0.26%) had VTE as the principal diagnosis for readmission within 90 days of initial hospital discharge. Among the 129,281 included ICH patients, the mean age was 68.5±0.1 years, 47.9% (61,967/129,281) were women, and 0.65% (843) had VTE as the principal diagnosis for a readmission within 90 days of initial hospital discharge. The VTE readmission rate per day declined over the 90-day period and the trend significantly decelerated after day 30 for AIS patients (P<0.001) and day 46 for ICH patients (P<0.001) (Figure 2).

Figure 2.

Trends in venous thromboembolism readmissions in (A) acute ischemic stroke (AIS) and (B) intracerebral hemorrhage (ICH) over 90 days.

Factors associated with VTE readmission on univariate analyses in AIS

In univariate analyses, when compared to AIS patients without a VTE readmission, those with a VTE readmission were more likely to be older (71.1±0.3 years vs. 70.0±0.1 years, P=0.002), women (54.6% vs. 49.6%, P<0.001), have a cancer diagnosis (10.8% vs. 4.0%, P<0.001), have congestive heart failure (17.6% vs. 15.5%, P=0.020), obesity (18.3% vs. 14.0%, P<0.001), have a higher NIHSS score (median [interquartile range, IQR]: 6 [3–14] vs. 4 [1–8], P<0.001), have Medicare insurance (71.7% vs. 66.7%, P<0.001), be treated at a metropolitan teaching hospital (73.1% vs. 70.6%, P=0.027), receive intravenous thrombolysis (11.2% vs. 9.4%, P=0.020), mechanical thrombectomy (5.8% vs. 3.5%, P<0.001), have a longer length of stay (median [IQR]: 5 days [3–8] vs. 3 days [2–6], P<0.001), and be discharged to a rehabilitation or skilled nursing facility (56.6% vs. 34.9%, P<0.001), and less likely to have atrial fibrillation or flutter (19.9% vs. 24.2%, P<0.001). Other characteristics were not significantly different between the two groups (Table 1).

Table 1.

Baseline characteristics across patients with vs. without VTE readmission in AIS and ICH

Factors associated with VTE readmission in AIS and ICH in Cox regression models

In Cox regression models, factors associated with increased rates of VTE readmission in patients with AIS were cancer (adjusted hazard ratios [aHR] 2.17, 95% confidence interval [CI] 1.63–2.90, P<0.001), obesity (aHR 1.73, 95% CI 1.42–2.10, P<0.001), higher NIHSS score (aHR 1.03 per point, 95% CI 1.02–1.04, P<0.001), longer hospital length of stay (aHR 1.03 per day, 95% CI 1.02–1.04, P<0.001), and disposition to home with services (aHR 1.60, 95% CI 1.22–2.11, P=0.001) or rehabilitation or nursing home (aHR 2.74, 95% CI 2.18–3.44, P<0.001) as opposed to disposition to home without services. On the other hand, atrial fibrillation was associated with a lower VTE readmission risk (aHR 0.57, 95% CI 0.45–0.71, P<0.001) (Table 2).

Table 2.

Variables associated with venous thromboembolism readmission in AIS and ICH patients in Cox regression analysis

In ICH patients, factors significantly associated with increased rates of VTE readmission were longer hospital length of stay (aHR 1.04 per day, 95% CI 1.01–1.06, P=0.005) and disposition to rehabilitation or nursing home (aHR 2.77, 95% CI 1.34–5.76, P=0.006) (Table 2).

Comparing VTE readmission risk between AIS and ICH

In the unadjusted analysis, when compared to AIS, ICH conferred a higher risk of VTE readmission (HR 2.56, 95% CI 2.28–2.87, P<0.001) (Figure 3). This finding persisted after adjusting for potential confounders (aHR 2.10, 95% CI 1.67–2.65, P<0.001), propensity score matching (aHR 1.89, 95% CI 1.34–2.66, P<0.001), and propensity weighted adjusted analyses (aHR 2.86, 95% CI 1.93–4.25, P<0.001) (Table 3).

Figure 3.

Kaplan-Meier survival estimates of venous thromboembolism readmission in acute ischemic stroke (AIS) vs. intracerebral hemorrhage (ICH).

Table 3.

Association of stroke type (ICH vs. AIS) with venous thromboembolism readmission in Cox regression models

Discussion

In this nationwide analysis of post-stroke patients, we found that the 90-day risk of VTE readmission is associated with factors linked to immobility and hypercoagulability. Furthermore, the risk of VTE readmission was highest in the first 30 days in AIS and 46 days in ICH and significantly decreased thereafter.

Some of our findings differed from prior studies. For instance, atrial fibrillation was shown to be associated with VTE after ischemic stroke in prior studies [12,13]. In our study atrial fibrillation was associated with lower risk of post-stroke VTE. The prior studies were conducted in the early 1990s when only 1.5% of their patients were treated with anticoagulation [13]. In current practice, these rates are substantially higher, particularly with anticoagulation by discharge being a joint commission quality measure in AIS patients with atrial fibrillation. Therefore, early initiation of oral anticoagulation in patients with atrial fibrillation according to current joint commission quality measures may be an important driver of reduced VTE risk in such patients. This notion is further supported by our observation that atrial fibrillation was not independently associated with VTE readmission risk after ICH, presumably because in such patients, initiation of oral anticoagulation may be delayed or considered contraindicated depending on the ICH etiology. Which again implies that the lower risk of VTE in atrial fibrillation patients may be due to anticoagulation therapy. Furthermore, the association between cancer and VTE risk in stroke patients is in line with studies suggesting the occurrence of hypercoagulability in the setting of cancer [14,15], which increases the risk of VTE [16]. Moreover, many risk factors for VTE readmission in our study have previously been linked to impaired mobility, such as increased hospital length of stay, stroke severity, discharge to a rehabilitation or skilled nursing facility, and obesity [17-20]. That said, there may be surveillance bias for facility disposition where VTE patients may more likely be sent to the hospital, and this finding should be interpreted with caution. Several studies have investigated extended VTE prophylaxis use in acutely ill medical patients and demonstrated decreased rate of VTE at a cost of increased rate of major bleeding. Stroke patients may have different coagulopathy (inherent disease or medication) and immobility than acutely ill medical patients. Further studies in this special subgroup patients are needed to test interventions such as early mobilization of stroke patients [21], reducing the length of hospital stay to reduce the VTE rates, shortterm use of mechanical and/or chemical DVT prophylaxis after hospital discharge, particularly in high-risk patients. Furthermore, standard doses of chemical prophylactic agents may not be as effective in obese patients [19,22].

Similar to prior studies [23,24], our study also showed that the risk of VTE was three-fold higher in ICH patients when compared to those with AIS. One possible explanation is the lower rates and delay in initiation of chemical VTE prophylaxis in ICH compared to AIS. Despite guidelines recommending chemical prophylaxis to be initiated between 1 and 4 days after ICH onset provided cessation of active bleeding [7], one study showed that less than 20% of patients with ICH received chemical VTE prophylaxis, of whom less than half of them received it within 2 days after ICH onset [24]. Patients with ICH are also more likely to require an intensive care unit admission, have higher morbidity, and have a longer length of hospital stay than patients with AIS, all of which may contribute to the higher risk of VTE in patients with ICH compared to those with AIS. Nevertheless, our findings suggesting higher rates of VTE in ICH patients persisted even after adjusting for these factors.

Finally, we found that rates of VTE are highest during the first 30 days after ischemic stroke and 46 days from ICH, which is consistent with prior studies [25,26]. This is in line with findings from prior studies showing the risk of VTE in stroke patients extends into the acute rehabilitation phase [12,27]. Thus studies are needed to investigate the efficacy and safety of continued mechanical and chemical prophylaxis beyond the hospital setting in high-risk patients and up to these time points with AIS and ICH. Furthermore, given the risk of VTE is significantly lower beyond these time points, long-term chemical or mechanical prophylaxis may not be beneficial and is not recommended by clinical guidelines [28].

There are several limitations to our study. Although this national database allows analysis of a very large number of patients, it lacks specific patient-level data. For example, despite accounting for multiple comorbidities, certain clinically relevant measures such as the use of anticoagulation and intermittent pneumatic compression are not available in this dataset. The national readmission database only provides disposition in limited categories, and it combines acute rehabilitation and skilled nursing facilities into one category. This is particularly important as patients who were discharged to long-term care have the most disability and the least potential for a good recovery than those discharged to acute rehabilitation. That said, the general criteria for discharge to acute rehabilitation are being unable to walk independently even with the use of an assistive device, which would imply a modified Rankin Scale score of 4 or 5 and thus have decreased mobility and are still at risk for VTE.

Importantly, we only considered patients who were hospitalized with VTE, and thus VTEs diagnosed and treated in the outpatient setting were not included. The rate of post-stroke VTE was reported to be up to 17% for asymptomatic and symptomatic patients and about 1% for clinically relevant events in prior studies [29,30]. Furthermore, patients with sudden death from an undiagnosed pulmonary embolus were also not included. These factors may have contributed to a lower rate of VTE in our study compared to prior studies [3]. Another limitation of our study is the exclusion of patients hospitalized between October and December. We however do not expect the variables and findings used in this study to vary based on this exclusion.

Conclusion

Although patients with stroke have a low rate of readmission for VTE, ICH and factors related to decreased mobility and/or hypercoagulability can put them at a higher risk of VTE. Further studies are needed to determine whether early mobilization and mechanical and/or short-term chemical prophylaxis post-discharge reduce the risk in high-risk patients.

Supplementary materials

Article information Continued